There had been a lot of hope for aticaprant, with GlobalData previously touting it as the most promising pipeline product for MDD due to its novel MOA and focus on anhedonia, a hard-to-treat symptom.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback